Safety and Efficacy of Exercise in Type-B Aortic Dissection
Condition(s) studied
Investigational drug(s) / intervention(s)
Exercise-based Cardiac Rehabilitation: Participated will receive 36 individualized Exercise-based Cardiac Rehabilitation after enrollment in our Cardiac Rehabilitation Center.
Study summary
This is a pilot study. The goal of this clinical trial is to evaluate the safety and efficacy of exercise-based cardiac rehabilitation in patients with Type-B Aortic dissection or intramural hematoma or penetrating ulcer and received endovascular repair. The main questions it aims to answer are:
• Is exercise-based cardiac rehabilitation safe among these patients? Participants will be randomly assigned to receive usual care plus exercise-based cardiac rehabilitation (guided exercise for 3 months in rehabilitation center) or usual care.
Eligibility
Primary outcome measure(s)
- Adverse events during exercise — 3 months
Rates of blood pressure increase ≥ 180/100 mmHg, new myocardial ischemia, and new arrhythmia during exercise; rates of dyspnea, palpitations, dizziness/syncope during exercise; and new chest pain/low back pain or worsening chest pain/low back pain - Aortic diameter — 3 months
The difference of aortic diameter before and after after 3-month intervention in mm. - Progression of dissection — 3 months
Increase in the number of aorta and its main branches involved in the dissection, the length of a single vessel dissection increases by more than 10 mm, or part of the dissected vessel ruptures - Endoleak — 3 months
Incidence of new endoleak after 3-month intervention.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Guangdong Provincial People's Hospital | Guangzhou | Guangdong | Recruiting |
More Guangdong Provincial People's Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07009067 on ClinicalTrials.gov ↗ ← All trials in China